ANNX Annexon

Annexon Biosciences to Present at the Jefferies Global Healthcare Conference

Annexon Biosciences to Present at the Jefferies Global Healthcare Conference

BRISBANE, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced that Douglas Love, president and chief executive officer, will present at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025 at 8:10 a.m. EST.

A live webcast of the event can be accessed under the ‘Events & Presentations’ section on the Investors page at . A replay of the webcast will be archived on the Annexon website for 30 days following the presentation.

About Annexon

Annexon Biosciences (Nasdaq: ANNX) is developing therapeutics that stop classical complement-driven neuroinflammation as first-in-kind treatments for millions of people living with serious neuroinflammatory diseases of the body, brain and eye. Our novel scientific approach focuses on C1q, the initiating molecule of classical complement’s potent inflammatory pathway that when misdirected can lead to tissue damage and loss. By targeting C1q, our immunotherapies are designed to stop this neuroinflammatory cascade in disease before it starts. Our pipeline spans three diverse therapeutic areas – autoimmune, neurodegenerative and ophthalmic diseases – and includes targeted investigational drug candidates designed to address the unmet needs of over 8 million people worldwide. Annexon’s mission is to deliver game-changing therapies to patients so that they can live their best lives. To learn more visit .

Investor Contact:

Joyce Allaire

LifeSci Advisors

Media Contact:

Sheryl Seapy

Real Chemistry

949-903-4750



EN
29/05/2025

Underlying

ANNXAnnexon

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Annexon

 PRESS RELEASE
Free
ANNX ANNEXON

Annexon Biosciences to Present at the TD Cowen 46th Annual Health Care...

Annexon Biosciences to Present at the TD Cowen 46th Annual Health Care Conference BRISBANE, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that Douglas Love, Esq., president and chief executive officer, will present at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026 at 9:50 a.m. ET. A live webcast of the event can be accessed under the ‘Events & ...

February 24, 2026 1 EN
 PRESS RELEASE
Free
ANNX ANNEXON

Annexon to Host In-Person and Virtual KOL Event to Discuss Vonaprument...

Annexon to Host In-Person and Virtual KOL Event to Discuss Vonaprument for the Treatment of Geographic Atrophy BRISBANE, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it will host an in-person and virtual key opinion leader (KOL) event in New York on Wednesday, March 18, 2026, with presentations at 2:00 PM ET and a reception at 4:00 PM ET. To register, . The event w...

February 17, 2026 1 EN
 PRESS RELEASE
Free
ANNX ANNEXON

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listin...

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) BRISBANE, Calif., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it has granted inducement to two new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on January 9, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4)....

January 16, 2026 1 EN
 PRESS RELEASE
Free
ANNX ANNEXON

Annexon Accelerating Next Generation Targeted Immunotherapy Platform f...

Annexon Accelerating Next Generation Targeted Immunotherapy Platform for Treatment of Neuroinflammatory Diseases with Multiple Registrational Milestones in 2026 Tanruprubart MAA Filed with Potential to Be the First Targeted Fast-Acting Therapy for Guillain-Barré Syndrome (GBS); BLA Submission with U.S./European Data Planned in 2026 Vonaprument Pivotal Phase 3 Topline Data for Dry AMD with Geographic Atrophy (GA) on Track for Second Half of 2026 Evaluating Unprecedented Effect on Vision Protection Proof-of-Concept Data for ANX1502, the First Oral C1 Inhibitor for Autoimmune Disease, Expect...

January 12, 2026 1 EN
 PRESS RELEASE
Free
ANNX ANNEXON

Annexon Submits Tanruprubart Marketing Authorization Application to th...

Annexon Submits Tanruprubart Marketing Authorization Application to the European Medicines Agency for Guillain-Barré Syndrome Potential to Be the First Targeted Fast-Acting Therapy for GBS, Setting a New Standard of Care BLA Submission with U.S./European Data from FORWARD Trial Planned in 2026 BRISBANE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced it has submitted a Marketing Auth...

January 8, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch